Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Carcinoma, Hepatocellular 4Recurrence 2Lymphoma, Non-Hodgkin 1Lymphoma 1Liver Neoplasms 1Hepatitis B 1

Interventions

Cyclophosphamide 27Rituximab 20Etoposide 14Cytarabine 13Melphalan 11Vincristine 10fludarabine 9Prednisone 9Doxorubicin 9Busulfan 8Peripheral Blood Stem Cell Transplantation 7Radiotherapy 6Filgrastim 6Cyclosporine 6Bendamustine Hydrochloride 6fludarabine phosphate 5N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 5Mycophenolic Acid 5Cisplatin 5tositumomab I-131 4ibritumomab tiuxetan 4Ifosfamide 4Dexamethasone 4Carmustine 4relmacabtagene autoleucel 3Thiotepa 3Indium 3Immunotherapy, Adoptive 3Gemcitabine 3Drug Therapy 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Lymphoma, Non-Hodgkin × Lamivudine × Clear all
NCT01914744 2013-08-02

Entecavir Versus Lamivudine for Preventing the Risk of Hepatitis B Reactivation in NHL

Fudan University

Phase 2 Unknown
82 enrolled
Lymphoid

Lymphoma, Non-Hodgkin

Data powered by HemOnc (CC BY 4.0) Colophon âš¡